BiologicalDrug
Sipuleucel-T clinical trials
Also written Provenge and APC8015.
- studies test it
- 23
- open now
- 3
- in phase 3
- 5
- first study started
- 1999
Keep track of what changes. Save the sipuleucel-T studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
23 studies that test it; most in 2011 (3)
| Year | Studies |
|---|---|
| 1999 | 1 |
| 2000 | 1 |
| 2001 | 1 |
| 2003 | 1 |
| 2008 | 2 |
| 2009 | 1 |
| 2011 | 3 |
| 2012 | 1 |
| 2013 | 3 |
| 2014 | 1 |
| 2016 | 2 |
| 2017 | 1 |
| 2018 | 1 |
| 2023 | 3 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 5
- Phase 2
- 13
- Phase 3
- 5
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 14 · Other 9
Dendreon (14) · The University of Texas Health Science Center, Houston (2) · University of Oklahoma (1) · University of Texas Southwestern Medical Center (1) · University of Hawaii (1) · Duke University (1) · Prostate Oncology Specialists, Inc. (1) · Washington University School of Medicine (1)
Often tested with
Tested in the same studies.
Docetaxel (2) · Abiraterone Acetate (1) · Abiraterone (1) · Enzalutamide (1) · Ipilimumab (1) · Booster (1) · Nogapendekin alfa inbakicept (1)
Studies
Open first, then newest update. How each study uses sipuleucel-T is read from its arms, and is right about nine times in ten.
Testing it · 23
- Sipuleucel-T Combined With Bipolar Androgen Therapy in Men With mCRPCRecruitingPhase 2Yale UniversityNCT06100705Written as Sipuleucel-T
- Sipuleucel-T (Sip-T) in Combination With N-803 in Metastatic Androgen Pathway Modulation Resistant (mAPMR) Prostate CancerNot yet recruitingPhase 1Washington University School of MedicineNCT07756593Written as Sipuleucel-T
- Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-TRecruitingPhase 2DendreonNCT06134232Written as Sipuleucel-T Injection
- Sipuleucel-T Based Autologous Cellular Immunotherapy for Advanced Prostate CancerActive, not recruitingPhase 1University of OklahomaNCT05806814Written as Sipuleucel-T
- Open- Label Trial of Sipuleucel-T Administered to Active Surveillance Patients for Newly Diagnosed Prostate CancerCompletedPhase 3DendreonNCT03686683Written as sipuleucel-T
- Sipuleucel-T and Stereotactic Ablative Body Radiation (SABR) for Metastatic Castrate-resistant Prostate Cancer (mCRPC)CompletedPhase 2University of Texas Southwestern Medical CenterNCT01818986Written as Sipuleucel-T
- Clinical Study of Atezolizumab (Anti-PD-L1) and Sipuleucel-T in Patients With Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate CancerCompletedPhase 1University of HawaiiNCT03024216Written as Sipuleucel-T
- Dendreon Lymph Node Biopsy in Metastatic Castrate-Resistant Prostate CancerCompletedPhase 1Duke UniversityNCT02036918Written as Sipuleucel-T
- Concurrent vs. Sequential Sipuleucel-T & Abiraterone Treatment in Men With Metastatic Castrate Resistant Prostate CancerCompletedPhase 2DendreonNCT01487863Written as sipuleucel-T
- A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate CancerCompletedPhase 2DendreonNCT01981122Written as sipuleucel-T
- PROvenge Treatment and Early Cancer TreatmentCompletedPhase 3DendreonNCT00779402Written as Sipuleucel-T
- Docetaxel Followed by Provenge in Metastatic Prostate CancerWithdrawnPhase 2The University of Texas Health Science Center, HoustonNCT02793765Written as Sipuleucel-T
- Provenge Followed by Docetaxel in Castration-Resistant Prostate CancerWithdrawnPhase 2The University of Texas Health Science Center, HoustonNCT02793219Written as Sipuleucel-T
- Sipuleucel-T and Ipilimumab for Advanced Prostate CancerCompletedPhase 1Prostate Oncology Specialists, Inc.NCT01832870Written as sipuleucel-T
- Sipuleucel-T in Metastatic Castrate Resistant Prostate CancerTerminatedPhase 2DendreonNCT01338012Written as sipuleucel-T
- Sequencing of Sipuleucel-T and ADT in Men With Non-metastatic Prostate CancerCompletedPhase 2DendreonNCT01431391Written as sipuleucel-T
- Open Label Study of Sipuleucel-T in Metastatic Prostate CancerCompletedPhase 2DendreonNCT00901342Written as sipuleucel-T
- To Evaluate Sipuleucel-T Manufactured With Different Concentrations of (PA2024) AntigenCompletedPhase 2DendreonNCT00715078Written as sipuleucel-T
- Sipuleucel-T Manufacturing Demonstration StudyCompletedPhase 2DendreonNCT01477749Written as sipuleucel-T
- Sipuleucel-T as Neoadjuvant Treatment in Prostate CancerCompletedPhase 2DendreonNCT00715104Written as Sipuleucel-T with Booster
See all 23 studies that test sipuleucel-T →
Given in every arm · 9 — sipuleucel-T is usual care beside what is tested
- 177^Lu-PSMA-617 in Combination With Sipuleucel-T for the Treatment of Metastatic Castration-Resistant Prostate CancerRecruitingPhase 1City of Hope Medical CenterNCT07219147Written as Sipuleucel-T
- Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate CancerActive, not recruitingPhase 2H. Lee Moffitt Cancer Center and Research InstituteNCT05751941Written as Sipuleucel-T
- Sipuleucel-T With or Without Radiation Therapy in Treating Patients With Hormone-Resistant Metastatic Prostate CancerCompletedPhase 2City of Hope Medical CenterNCT01807065Written as sipuleucel-T
- Sipuleucel-T With or Without Tasquinimod in Treating Patients With Metastatic Hormone-Resistant Prostate CancerCompletedPhase 2Roswell Park Cancer InstituteNCT02159950Written as Sipuleucel-T
- Sipuleucel-T With Immediate vs. Delayed Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Blockade for Prostate CancerCompletedPhase 2University of California, San FranciscoNCT01804465Written as SipT Treatment
- Study of Sipuleucel-T W/ or W/O Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-MCRPCCompletedPhase 2Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT02463799Written as Sipuleucel-T
- Provenge With or Without pTVG-HP DNA Booster Vaccine in Prostate CancerCompletedPhase 2University of Wisconsin, MadisonNCT01706458Written as sipuleucel-T
- Phase II Study of Sipuleucel-T and Indoximod for Patients With Refractory Metastatic Prostate CancerCompletedPhase 2Masonic Cancer Center, University of MinnesotaNCT01560923Written as Sipuleucel-T
- APC8015 and Bevacizumab in Treating Patients With Prostate CancerCompletedPhase 2National Cancer Institute (NCI)NCT00027599Written as sipuleucel-T
Codes
What other systems call sipuleucel-T · ClinicalTrials.gg INT004936
- MeSH (NLM) C511774sipuleucel-TConfirmed NLM, Wikidata
- UNII (FDA) 8Q622VDR18SIPULEUCEL-TConfirmed FDA, NLM, Wikidata
- RxNorm 997261Confirmed FDA, Wikidata
- Wikidata Q424057sipuleucel-TConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C1985Sipuleucel-TConfirmed FDA, Wikidata
- DrugBank DB06688One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C511774 | sipuleucel-T | Confirmed NLM, Wikidata |
| UNII (FDA) | 8Q622VDR18 | SIPULEUCEL-T | Confirmed FDA, NLM, Wikidata |
| RxNorm | 997261 | — | Confirmed FDA, Wikidata |
| Wikidata | Q424057 | sipuleucel-T | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C1985 | Sipuleucel-T | Confirmed FDA, Wikidata |
| DrugBank | DB06688 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.